Mumbai: Serum Institute of India Pvt. Ltd., part of Cyrus Poonawalla Group, and Vidal Health, a 100 percent subsidiary of Bajaj Finserv Health, India's TPA service provider, have announced a strategic collaboration to enhance cervical cancer prevention and awareness across the country.

Starting October 1, 2025, Vidal Health’s platform will offer an end- to-end, convenient and cashless experience for HPV vaccine – from digitally booking a doctor’s appointment at a preferred location, to providing consent and receiving certification - all with zero paperwork. The fully managed health programme will provide complete support with timely dosage reminders, adherence monitoring, and efficient network management to ensure continuity of care.

Vidal Health is a 100% subsidiary of Bajaj

See Full Page